Quick Answer
Cadrenal Therapeutics, Inc. reported Operating Income Loss of -$13.46 million for the year ending 2025.
- Cadrenal Therapeutics, Inc. showed a decrease of -22.8% in Operating Income Loss from 2024 to 2025.
- This data is from Cadrenal Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$170.5 thousand | Q2 2022: -$482.3 thousand | Q3 2022: -$972.8 thousand | Q1 2023: -$4.20 million | Q2 2023: -$1.03 million | Q3 2023: -$1.14 million | Q1 2024: -$1.76 million | Q2 2024: -$2.47 million | Q3 2024: -$2.46 million | Q1 2025: -$3.93 million | Q2 2025: -$3.73 million | Q3 2025: -$2.73 million.
- Over the full 4 years of available data (2022 to 2025), Cadrenal Therapeutics, Inc.'s Operating Income Loss has declined by 398.3%.
- Historical annual values: Fiscal year 2025: -$13.46 million | Fiscal year 2024: -$10.96 million | Fiscal year 2023: -$7.63 million | Fiscal year 2022: -$2.70 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: